CIDRAP newsletters options
People with disabilities had 36% longer COVID-19 hospital stays and 77% more readmissions.
Pre-Omicron data show 93% protection against COVID-19 and 98% protection against severe COVID-19.
The secondary attack rate was shown higher in Denmark for BA.2 than the original Omicron—39% vs 29%.
Significantly fewer adult Medicare beneficiaries with schizophrenia or bipolar 1 disorders had mental health-related outpatient, emergency department (ED), and hospital visits, as well as fills for antipsychotics and mood-stabilizing drugs in the first 8 months of the COVID-19 pandemic.
A multifaceted stewardship intervention aimed at virtual visits was tied to improvements in guideline-concordant antibiotic prescribing for upper respiratory tract infections (URTIs) and sinusitis, University of Michigan researchers reported today in Infection Control & Hospital Epidemiology.
One study finds that 2 vaccinated parents are better than 1 at protecting kids.
Also, people are concerned about the impact of Omicron on the economy and on hospitals.
New rules limiting the use of antibiotics in food-producing animals in the European Union went into effect today.
A third COVID-19 vaccine dose increased vaccine effectiveness (VE) against hospitalization from 82% to 97% among adults with healthy immune systems and from 69% to 88% among those with impaired immunity, according to a study today in Morbidity and Mortality Weekly Report (MMWR).
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
Both studies show promise for boosters against Omicron, with one focusing on dose interval.
Also, the ECDC says the BA.2 subvariant is now dominant in Denmark and is rising elsewhere.
US hospital data show 150,000 COVID-19 patients being treated, down from a record 160,000.
"Without antibiotics, we are set back 100 years."
China has reported two more human H5N6 avian influenza infections from two different provinces, part of a small but steady stream of illnesses involving the strain, according to a statement today from Hong King's Centre for Health Protection (CHP).
Among 457 adult participants in an ongoing phase 1/2 clinical trial who completed primary COVID-19 vaccination with the Moderna, Johnson & Johnson (J&J), or Pfizer/BioNTech vaccines, a booster dose with either the same (homologous) or a different brand (heterologous) induced an immune response and was safe.
Officials confirmed more than 21 million new global cases last week, the highest weekly total ever.
COVID has compounded how the lack of country-of-origin data can affect drug safety, affordability, availability, and national security.
Higher levels of resistance were observed in southern and eastern Europe.
Overall, patients had only modest benefit, but some subgroups fared better.
